New drug cocktail aims to fight Hard-to-Treat cancers

NCT ID NCT06953323

Recruiting now Disease control Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks tumors. About 86 participants will be enrolled, and the goal is to determine if this combination is safe and worth further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WJB001 (Wee1 inhibitor) combined with chemotherapy drugs like paclitaxel, carboplatin, or other targeted agents
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the results may not apply to everyone. The combination therapy may cause significant side effects, and it is too soon to know if it will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma fallopian tube cancer neoplasm ovarian serous adenocarcinoma peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350000, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410000, China
Liaoning Cancer Hospital
RECRUITING

Shenyang, Liaoning, 110000, China
Sun Yat-sen Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Gunagdong, 510000, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510000, China
The First Affiliated Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110000, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China
Tumor Hospital Affiliated to Guangxi Medical University
RECRUITING

Nanning, Guangxi, 530000, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430023, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.